MedTrace Logo

A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee

NCT01529671 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2012-12-12

No results posted yet for this study

Summary

The purpose of the study is primarily to determine the safety and toleration and pharmacokinetics of PF-05089771 following escalating multiple doses lasting for 14 days.

Conditions

Interventions

DRUG

PF-05089771

PF-05089771 will be dosed as a suspension twice daily (BID)

DRUG

PF-05089771

PF-05089771 will be dosed as a suspension twice daily (BID)

DRUG

PF-05089771

PF-05089771 will be dosed as a suspension twice daily (BID)

DRUG

PF-05089771

PF-05089771 will be dosed as a suspension twice daily (BID)

DRUG

PF-05089771

PF-05089771 will be dosed as a suspension BID

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01529671 on ClinicalTrials.gov